Literature DB >> 11557112

Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis.

H Sasaki1, L B Chen, D Auclair, S Moriyama, M Kaji, I Fukai, M Kiriyama, Y Yamakawa, Y Fujii.   

Abstract

We used palindromic PCR-driven cDNA differential display technique to identify and isolate a gene, human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, from colon cancer tissues. The loss of checkpoint control in mammalian cells results in genomic instability, leading to the amplification, rearrangement, or loss of chromosomes, events associated with tumor progression. We hypothesized that the Hrad17 may be expressed in non-small cell lung cancer (NSCLC). We attempted to determine the influence of Hrad17 expression on clinicopathological features for patients with NSCLC who had undergone surgery. Expression of Hrad17 messenger RNA was evaluated by reverse transcription-polymerase chain reaction (RT-PCR) in 102 non-small cell lung carcinomas and adjacent histologically normal lung samples from patients for whom follow up data were available. Hrad17 transcripts were detected in 26 (25.5%) of the tumor samples, although some of the paired normal lung samples showed weak expression. There was no relationship between Hrad17 gene expression and age, gender or T-status. About 13 of 31 (41.9%) NSCLC patients with Hrad17 overexpressions were node positive, on the other hand, 13 of 76 (18.3%) cases without Hrad17 overexpressions were node positive. Thus the expression of Hrad17 mRNA correlated with lymph node metastasis (P=0.0231) from NSCLC. Hrad17 protein was highly expressed at the advancing margin of the tumor of lung cancer tissue but not within the normal lung tissue by immunohistochemistry. Thus the expression of Hrad17 might correlate with more advanced NSCLC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557112     DOI: 10.1016/s0169-5002(01)00223-9

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  7 in total

1.  Regulation of Rad17 protein turnover unveils an impact of Rad17-APC cascade in breast carcinogenesis and treatment.

Authors:  Zhuan Zhou; Chao Jing; Liyong Zhang; Fujita Takeo; Hyun Kim; Yi Huang; Zhihua Liu; Yong Wan
Journal:  J Biol Chem       Date:  2013-05-01       Impact factor: 5.157

Review 2.  DNA damage response genes and the development of cancer metastasis.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

3.  Genetic polymorphism at codon 546 of the human RAD17 contributes to the risk for esophageal squamous cell carcinoma.

Authors:  Yukiko Yasuda; Akiko Sakai; Sachio Ito; Yuichiro Mita; Takayuki Sonoyama; Shunsuke Tanabe; Yasuhiro Shirakawa; Yoshio Naomoto; Hiroshi Katayama; Kenji Shimizu
Journal:  Int J Mol Epidemiol Genet       Date:  2016-03-23

4.  Hrad17 expression in thymoma.

Authors:  Hidefumi Sasaki; Yoshihiro Kobayashi; Haruhiro Yukiue; Motoki Yano; Masahiro Kaji; Ichiro Fukai; Masanobu Kiriyama; Yosuke Yamakawa; Yoshitaka Fujii
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-03

5.  Differential hRad17 expression by histologic subtype of ovarian cancer.

Authors:  Jennifer L Young; E Colin Koon; Joseph Kwong; William R Welch; Michael G Muto; Ross S Berkowitz; Samuel C Mok
Journal:  J Ovarian Res       Date:  2011-03-30       Impact factor: 4.234

6.  The noncoding function of NELFA mRNA promotes the development of oesophageal squamous cell carcinoma by regulating the Rad17-RFC2-5 complex.

Authors:  Jiancheng Xu; Guangchao Wang; Wei Gong; Shichao Guo; Dan Li; Qimin Zhan
Journal:  Mol Oncol       Date:  2020-01-28       Impact factor: 6.603

7.  Differential expression profiling of head and neck squamous cell carcinoma (HNSCC).

Authors:  F Lemaire; R Millon; J Young; A Cromer; C Wasylyk; I Schultz; D Muller; P Marchal; C Zhao; D Melle; L Bracco; J Abecassis; B Wasylyk
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.